The Private Label
AI Advantage

This is the franchise’s strongest result.

5W modeled the Citation Share of 25 over-the-counter health brands: 13 store-brand OTC lines against 12 national OTC brands, across five answer engines and 64 consumer-intent prompts. Store-brand OTC earned an average Citation Share of 45. National OTC brands earned 25.

OTC is the category where the private label AI advantage is not just wide — it is active. In grocery, AI surfaces store brands. In OTC, answer engines go further: they routinely tell shoppers, in plain language, that the store brand contains the identical active ingredient as the national brand at a fraction of the price. The single most-cited fact in the category is a structural argument for the store brand.

National OTC brands built the most valuable names in retail healthcare — Tylenol, Advil, Claritin. Answer engines treat those names as starting points for a comparison that ends with the store brand.

Over-the-counter medicine moved to the answer layer with a fact no other category carries: the products are often chemically identical.

Over-the-counter medicine has a property no other consumer category shares: the products are, by regulation, often chemically identical. Equate ibuprofen and Advil contain the same active ingredient at the same dose. This is not a marketing claim — it is printed on both boxes, and it is the most repeated fact in OTC content across the web.

Answer engines retrieve and state that fact directly. Ask one “is store-brand ibuprofen as good as Advil” and the answer is an unambiguous yes, with the price difference attached. In grocery, “best value” is a judgment. In OTC, it is closer to arithmetic — and answer engines are very good at arithmetic.

The national OTC brand’s entire defense — brand trust — is the one asset a same-active-ingredient comparison neutralizes.

Franchise-standard. 25 OTC brands — 13 store-brand lines, 12 national — scored across five answer engines on 64 consumer-intent prompts spanning six sub-categories. Prompts mirror real shopper language, with no brand names seeded.

Citation Share is a directional visibility model measuring how frequently brands, retailers, and experts appear across AI-generated answers inside ChatGPT, Claude, Gemini, Perplexity, and Google AI Overviews. Scores are indexed 0–100, estimated from current answer-engine behavior and the structure and density of the open-web content each brand can be surfaced from. It is a model of the retrieval landscape — not a logged-query count, which is unstable and easily gamed.

Example prompts tested

Modeled Citation Share across all five answer engines. Click any column header to sort.

The top six positions are all store brands. The strongest national brand — Tylenol — does not appear until #7, and ranks there precisely because “Tylenol” functions as a near-generic term for acetaminophen.

Store-brand OTC leads on all five engines, and the gap is the most consistent in the franchise — because the underlying fact is platform-independent.

Perplexity and ChatGPT show the widest gaps; both readily produce the explicit “same ingredient, lower price” comparison. Claude does the same, with careful framing. Gemini and Google AI Overviews also favor store brands, slightly less aggressively, as Google’s index carries more national-brand search authority. On no engine do national OTC brands lead.

Store brands win all six sub-categories — the only clean sweep in the franchise.

The margin is widest in Pain Relief and Allergy, where active-ingredient equivalence is most widely understood and discussed — ibuprofen, acetaminophen, loratadine, cetirizine. It is narrowest, though still a store-brand win, in Cold & Flu and Sleep & Topicals, where multi-symptom national brands like Nyquil retain some brand-as-category pull. There is no national-brand stronghold sub-category. That absence is the story.

Answer engines recommend store-brand OTC because every retrieval input points the same direction — and one of them is a regulator-enforced fact:

Five of the six inputs are unusually strong for store brands — and the sixth, ingredient-equivalence content, is not a soft signal but a hard, regulator-enforced fact the open web repeats endlessly. No other category gives answer engines such a clean, verifiable basis to recommend the cheaper option. For once, the community layer and the expert layer point the same way: both at the store brand.

Which sources shape the answer

Conversational retrieval draws on a measurable source mix. In OTC, the most influential sources all point the same direction — toward the store brand.

National OTC brands are the franchise’s clearest losers. Their core asset — a trusted name — is precisely what a same-ingredient comparison erodes. Sudafed, Nyquil, Robitussin, Tums, Aleve sit at the bottom: strong names, under-cited, recommended (when at all) as the more expensive option.

Even Tylenol and Advil, the category’s most powerful brands, rank only mid-table — and largely because their names have become shorthand for their active ingredients, which is its own long-term vulnerability.

OTC is where all four answer-engine rewards align perfectly with the store brand — simplicity, trust density, content recency, value clarity — and a fifth factor joins them: factual equivalence. A regulator-enforced, web-documented fact that the cheaper product is the same product.

Answer engines are built to surface exactly that kind of clean, verifiable fact. This is not an architecture match. It is an architecture match with the category’s central fact acting as an accelerant.

Legacy advantage vs AI-era advantage

The shift is not cosmetic. It is a change in which assets generate visibility.

The halo is at its most consequential in OTC. A shopper who trusts CVS as a pharmacy extends that trust to CVS Health-branded medicine without hesitation. The pharmacy halo is the strongest version of the effect 5W has modeled: it converts a retailer’s clinical credibility directly into store-brand Citation Share — which is why Equate and CVS Health hold the top two positions in the index.

Two content layers compound here. Community discussion — Reddit threads, forums — is overwhelmingly pro-store-brand, full of “just buy the generic” advice. And expert content agrees: pharmacist commentary, consumer-health journalism, and medical explainers almost uniformly endorse generic OTC equivalence.

For once, the community layer and the credentialed-authority layer point the same direction — both at the store brand. That alignment is why OTC has no national-brand firewall.

Common thread: in OTC, brand equity is the asset under attack. A same-ingredient comparison turns a century of brand-building into a price premium an answer engine flags.

Private-label OTC already holds close to half the category by value and is growing several times faster than national brands. AI search is positioned to push that further and faster than in any other category — because the answer engine does the persuasion the store brand used to need shelf placement and price stickers to do.

For national OTC brands, this is the franchise’s most urgent warning: the defense cannot be the brand name. It has to be genuine, communicable, AI-legible differentiation — faster onset, a cleaner formulation, a combination product — or the erosion compounds answer by answer.

For national OTC brands, the playbook is not brand defense. It is building a real difference an answer engine can retrieve.

1. Stop defending the name; build a real difference. Faster onset, cleaner formulation, a combination product, a better format — something a same-ingredient comparison cannot neutralize.
2. Make the difference retrievable. The content establishing it must be dense, credible, and current on sources answer engines trust.
3. For retailers, protect the pharmacy halo. Clinical reputation is the asset; the OTC line compounds with it.
4. Own the comparison prompt. “Store brand vs name brand” is, in OTC, the category. Measure and shape that single answer.
5. Track Citation Share on a fixed cadence. In a category eroding answer by answer, an untracked metric is an unmanaged one.

The principle underneath all five: build the infrastructure before the crisis — not during it.

Limitations. Directional model, May 2026. Scores measure AI visibility, not medical guidance — nothing here is health advice; active-ingredient equivalence does not mean products are identical in every respect, and that nuance matters. Brand set is 25 of the most relevant OTC brands.

Outlook. Store-brand OTC’s advantage is structural and accelerating; the only national-brand path is genuine differentiation, not brand defense. OTC is the franchise’s strongest proof of the thesis — the category where AI does not just favor the store brand, it explains why.

Glossary

▸ Citation Share

The modeled frequency with which a brand appears across AI-generated answers for a defined set of buyer questions. Indexed 0–100; the answer-engine equivalent of share of voice.

▸ Answer-Layer Visibility

A brand's presence inside the AI-generated answer a buyer reads before reaching a shelf or a search result — the competitive surface that now precedes market share.

▸ Retrieval Authority

The strength and consistency of the open-web signal an answer engine draws on when deciding which brands to surface for a query.

▸ Trust Density

The concentration of credible, independent signals — reviews, community discussion, expert mentions, verification — attached to a brand. Answer engines reward it heavily.

▸ Recommendation Frequency

How often a brand is actively recommended, not merely mentioned, across answer engines for category-defining prompts.

▸ Retailer Halo Effect

The transfer of a retailer's reputation onto its private brand. Answer engines reinforce that inherited trust signal, citing the brand as though the retailer's credibility were its own.